T-lymphoblastic Lymphoma Clinical Trials

23 clinical trials for T-lymphoblastic Lymphoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma — RECRUITING · PHASE2
• Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies — RECRUITING · PHASE1
• Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) — RECRUITING · PHASE1
• Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma — RECRUITING · PHASE1
• Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma — RECRUITING · PHASE1
• CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study — RECRUITING · PHASE1
• Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) — NOT_YET_RECRUITING · PHASE2
• A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma — NOT_YET_RECRUITING · PHASE1
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma — COMPLETED · PHASE3
• Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL — NOT_YET_RECRUITING · PHASE1
• Cryopreserved MMUD BM With PTCy for Hematologic Malignancies — WITHDRAWN · PHASE1
• Allo-HSCT vs ASCT in Adult T-LBL — NOT_YET_RECRUITING · NA
• The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma — OTHER · PHASE3
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) — WITHDRAWN · PHASE2
• Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL — OTHER · NA
• Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies — SUSPENDED · PHASE1
• Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia — OTHER · PHASE2
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — TERMINATED · PHASE2
• A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL — WITHDRAWN · PHASE1
• RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL — OTHER · NA
• CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia — OTHER · PHASE1
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma — WITHDRAWN · PHASE2
• A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma — OTHER · PHASE4

Refine this search